ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,105Medicare Part D Prescriptions Filled, Including Refills

Rank: 18 out of 224

$417K Total Retail Price of All Prescriptions

Rank: 24 out of 224

258 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
59% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Vermont
Lower avg

Schedule Two
Controlled Substances

16% of this provider’s 258 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

21% of this provider’s 258 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

1% of this provider’s 5,682 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Vermont
SIMVASTATIN 392 341 1 1
OMEPRAZOLE 271 211 2 3
METOPROLOL SUCCINATE 198 188 3 11
LEVOTHYROXINE SODIUM 190 164 4 4
METOPROLOL TARTRATE 181 174 5 7
AMLODIPINE BESYLATE 179 177 6 8
HYDROCHLOROTHIAZIDE 176 154 7 6
HYDROCODONE-ACETAMINOPHEN 169 124 S3 8 12
FUROSEMIDE 164 143 9 5
ENALAPRIL MALEATE 157 129 10 42
SPIRIVA 128 112 11 32
GABAPENTIN 124 66 12 14
METFORMIN HCL 113 84 13 9
CITALOPRAM HBR 105 84 14 15
WARFARIN SODIUM 100 98 15 10
PRAVASTATIN SODIUM 100 81 15 21
POTASSIUM CHLORIDE 85 79 17 24
ADVAIR DISKUS 85 69 17 23
ATENOLOL 83 77 19 13
OXYCODONE-ACETAMINOPHEN 83 22 S2 19 41
LYRICA 79 58 21 85
LISINOPRIL 73 69 22 2
LOSARTAN POTASSIUM 72 63 23 19
DONEPEZIL HCL 71 71 24 36
ATORVASTATIN CALCIUM 69 58 25 16
RANITIDINE HCL 69 36 25 29
IBUPROFEN 66 48 27 51
TRAZODONE HCL 65 51 28 20
AZITHROMYCIN 64 49 29 46
PREDNISONE 63 55 30 28
CIPROFLOXACIN HCL 59 36 31 95
CYCLOBENZAPRINE HCL 58 26 R 32 76
CLOPIDOGREL 54 54 33 70
ZOLPIDEM TARTRATE 53 26 34 22
FENTANYL 52 33 S2 35 49
OXYCODONE HCL 51 14 S2 36 25
DILTIAZEM 24HR ER 50 42 37 84
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.